A Phase 3 interventional study of Evolocumab and Atorvastatin in Diabetes, Hyperlipidemia, Mixed Dyslipidemia, sponsored by Amgen. Completed at 110 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-01-11.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 417 studies in Diabetes Mellitus with a site in China — 100 open to participants now, 117 under way, 11 of them phase 3. Diabetes Mellitus · China.
Among the 417 studies in Diabetes Mellitus with a site in China, this one is the 29th largest by enrollment of the 280 interventional ones that give a count, is one of 19 that started in 2016, is one of 36 in phase 3, and was the 142nd registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →100 of the 417 studies in Diabetes Mellitus with a site in China are open now. Recruiting first, the newest first:
China Medical University, China · Sites in China
Ages 50–75
CSL Behring · Sites in China
Ages 18+
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
417 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 25 · Phase 3 41 · Phase 4 52
First in 2002; this study’s year is marked. 19 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 986 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 143 across the 280 interventional studies, 605 across the 137 observational. Of the 204 that completed or were terminated, 47 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 417 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 9 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
19 of the studies in Diabetes Mellitus with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06309082First Affiliated Hospital of Wenzhou Medical UniversityAssessing Diabetic Foot Ulcer Microcirculation With High-frequency Contrast Enhanced Ultrasound | 2026-12 |
| NCT05105321Tang YidaCardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP) | 2026-12 |
| NCT07489482Jiangsu HengRui Medicine Co., Ltd.A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection | 2026-12 |
| NCT06959784China-Japan Friendship HospitalAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) | 2026-12-31 |
| NCT06958640China-Japan Friendship HospitalDa Qing Offspring Study | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 417 studies in Diabetes Mellitus with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in diabetic adults with hyperlipidemia or mixed dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.
Drug: Atorvastatin · Other: Placebo
Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.
Drug: Atorvastatin · Other: Placebo
Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.
Biological: Evolocumab · Drug: Atorvastatin
Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.
Biological: Evolocumab · Drug: Atorvastatin
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered orally once a day
Also known as: Lipitor
Placebo to evolocumab administered by subcutaneous injection
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in LDL-C at Week 12
Time frame: Baseline and week 12
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Change From Baseline in LDL-C at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Non-HDL-C at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B100 at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Total Cholesterol at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 12
Time frame: Baseline and week 12
Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)
Time frame: Weeks 10 and 12
Percentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 12
Time frame: Week 12
Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Lipoprotein(a) at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in Triglycerides at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Percent Change From Baseline in HDL-C at Week 12
Time frame: Baseline and week 12
Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and weeks 10 and 12
Participants were enrolled at 102 study centers and randomized at 98 centers in Argentina, Brazil, Canada, China, Colombia, France, Republic of Korea, Russian Federation, Turkey, and the United States from 14 April 2016 to 28 July 2017.
| Milestone | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Started | 166 | 161 | 327 | 332 |
| Received study drug | 164 | 160 | 325 | 332 |
| Completed | 159 | 160 | 321 | 328 |
| Not completed | 7 | 1 | 6 | 4 |
| Withdrew: Withdrawal by subject | 6 | 1 | 6 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | 4.94 ± 3.48 | 0.99 ± 3.31 | -65.35 ± 3.09 | -69.05 ± 2.96 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in LDL-C at Week 12 | 7.10 ± 3.66 | 2.63 ± 3.41 | -64.66 ± 3.20 | -62.30 ± 3.02 |
| mg/dL | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | -2.1 ± 4.1 | -8.8 ± 4.0 | -64.6 ± 3.6 | -71.9 ± 3.6 |
| mg/dL | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Change From Baseline in LDL-C at Week 12 | -0.3 ± 4.2 | -7.3 ± 4.1 | -63.9 ± 3.7 | -66.1 ± 3.7 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12 | 4.33 ± 3.05 | 0.33 ± 2.95 | -56.57 ± 2.70 | -59.08 ± 2.63 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 | 5.87 ± 3.20 | 1.30 ± 3.03 | -55.76 ± 2.79 | -52.92 ± 2.69 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 12 | 1.97 ± 3.31 | -1.52 ± 2.99 | -54.96 ± 3.07 | -56.37 ± 2.72 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B100 at Week 12 | 3.17 ± 3.42 | -0.26 ± 3.03 | -53.90 ± 3.14 | -49.68 ± 2.75 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12 | 2.89 ± 2.30 | -0.25 ± 2.18 | -38.64 ± 2.04 | -39.74 ± 1.95 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 12 | 4.40 ± 2.40 | 0.67 ± 2.24 | -37.82 ± 2.10 | -35.22 ± 1.99 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12 | 3.03 ± 2.38 | -2.03 ± 2.41 | -41.06 ± 2.11 | -45.70 ± 2.17 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12 | 3.22 ± 2.49 | -1.22 ± 2.47 | -40.72 ± 2.18 | -41.78 ± 2.21 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12 | 2.60 ± 3.30 | -1.02 ± 3.09 | -55.60 ± 3.07 | -57.75 ± 2.82 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 12 | 3.23 ± 3.39 | -0.10 ± 3.16 | -54.98 ± 3.12 | -51.80 ± 2.86 |
| percentage of participants | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L) | 21.7 (15.9 to 28.7) | 19.4 (13.9 to 26.3) | 90.1 (86.2 to 92.9) | 91.3 (87.6 to 93.9) |
| percentage of participants | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 12 | 20.9 (15.2 to 28.2) | 21.3 (15.5 to 28.6) | 88.2 (84.0 to 91.4) | 90.2 (86.2 to 93.1) |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12 | 16.89 ± 17.49 | 8.48 ± 9.49 | -38.63 ± 13.67 | -42.29 ± 8.49 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 12 | 26.53 ± 21.78 | 7.47 ± 10.40 | -35.93 ± 16.47 | -37.85 ± 9.02 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12 | 11.54 ± 5.27 | 8.48 ± 4.48 | -6.48 ± 4.70 | -7.15 ± 4.02 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 12 | 10.50 ± 5.36 | 8.07 ± 4.57 | -5.91 ± 4.75 | -4.24 ± 4.09 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12 | 1.25 ± 2.19 | 5.88 ± 2.11 | 7.59 ± 1.99 | 13.75 ± 1.90 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 | 2.57 ± 2.29 | 6.04 ± 2.18 | 8.45 ± 2.04 | 14.18 ± 1.95 |
| percent change | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12 | 9.63 ± 4.70 | 7.92 ± 4.43 | -17.55 ± 4.19 | -16.09 ± 3.99 |
Collected over From the first dose of study drug to 30 days after last dose; up to 14 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | 0/164 (0%) | 6/164 (3.7%) | 28/164 (17.1%) |
| Placebo QM | 0/160 (0%) | 5/160 (3.1%) | 22/160 (13.8%) |
| Evolocumab Q2W | 0/325 (0%) | 10/325 (3.1%) | 45/325 (13.8%) |
| Evolocumab QM | 0/332 (0%) | 22/332 (6.6%) | 49/332 (14.8%) |
| Event | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 2/164 | 0/160 | 0/325 | 2/332 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/164 | 0/160 | 0/325 | 3/332 |
| CataractEye disorders | 0/164 | 1/160 | 0/325 | 1/332 |
| Lung infectionInfections and infestations | 0/164 | 1/160 | 0/325 | 0/332 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/164 | 1/160 | 0/325 | 0/332 |
| Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/164 | 1/160 | 0/325 | 0/332 |
| Carotid artery stenosisNervous system disorders | 0/164 | 1/160 | 0/325 | 0/332 |
| Ischaemic strokeNervous system disorders | 0/164 | 1/160 | 0/325 | 0/332 |
| Cerebral infarctionNervous system disorders | 0/164 | 0/160 | 2/325 | 0/332 |
| Herpes zoster cutaneous disseminatedInfections and infestations | 1/164 | 0/160 | 0/325 | 0/332 |
| Event | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|
| Diabetes mellitusMetabolism and nutrition disorders | 2/164 | 4/160 | 15/325 | 15/332 |
| Upper respiratory tract infectionInfections and infestations | 6/164 | 5/160 | 9/325 | 13/332 |
| NasopharyngitisInfections and infestations | 6/164 | 6/160 | 9/325 | 11/332 |
| HypertensionVascular disorders | 6/164 | 3/160 | 8/325 | 5/332 |
| HypoglycaemiaMetabolism and nutrition disorders | 5/164 | 0/160 | 2/325 | 2/332 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/164 | 4/160 | 3/325 | 3/332 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/164 | 2/160 | 1/325 | 6/332 |
| Age, Continuous(years) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Mean | 61.6 ± 8.8 | 61.0 ± 8.8 | 61.0 ± 8.5 | 61.6 ± 8.4 | 61.3 ± 8.6 |
| Age, Customized(Participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| 18 - 64 years | 105 | 101 | 206 | 208 | 620 |
| 65 - 80 years | 61 | 60 | 121 | 124 | 366 |
| Sex: Female, Male(Participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Female | 102 | 94 | 178 | 190 | 564 |
| Male | 64 | 67 | 149 | 142 | 422 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 29 | 34 | 65 | 67 | 195 |
| Not Hispanic or Latino | 137 | 127 | 262 | 265 | 791 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 0 | 2 |
| Asian | 82 | 80 | 164 | 166 | 492 |
| Black or African American | 7 | 6 | 11 | 18 | 42 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 72 | 68 | 140 | 140 | 420 |
| Multiple | 5 | 6 | 11 | 8 | 30 |
| Stratification Factor: Statin Therapy at Study Entry(Participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Intensive statin usage | 16 | 15 | 31 | 32 | 94 |
| Non-intensive statin usage | 83 | 80 | 167 | 166 | 496 |
| No statin | 67 | 66 | 129 | 134 | 396 |
| Stratification Factor: Geographic Region(Participants) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| China | 76 | 75 | 150 | 152 | 453 |
| South Korea | 6 | 5 | 14 | 13 | 38 |
| Other countries | 84 | 81 | 163 | 167 | 495 |
| Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL) | Placebo Q2W | Placebo QM | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|
| Mean | 92.2 ± 32.0 | 91.0 ± 30.7 | 92.4 ± 33.8 | 93.5 ± 33.6 | 92.5 ± 32.9 |
9 further baseline measures are reported on the registry.
Showing the first 100 of 110 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in Dec 2017, 19 months.
Results were first posted in Jan 2019, 1 year 1 month after primary completion.
Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 19 months is above that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab